JP2020535180A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535180A5 JP2020535180A5 JP2020517814A JP2020517814A JP2020535180A5 JP 2020535180 A5 JP2020535180 A5 JP 2020535180A5 JP 2020517814 A JP2020517814 A JP 2020517814A JP 2020517814 A JP2020517814 A JP 2020517814A JP 2020535180 A5 JP2020535180 A5 JP 2020535180A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- compound
- cancer
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17194196 | 2017-09-29 | ||
| EP17194196.6 | 2017-09-29 | ||
| PCT/EP2018/076494 WO2019063802A1 (en) | 2017-09-29 | 2018-09-28 | ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535180A JP2020535180A (ja) | 2020-12-03 |
| JP2020535180A5 true JP2020535180A5 (https=) | 2021-11-11 |
Family
ID=60009481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517814A Pending JP2020535180A (ja) | 2017-09-29 | 2018-09-28 | 抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200239559A1 (https=) |
| EP (1) | EP3687573A1 (https=) |
| JP (1) | JP2020535180A (https=) |
| CN (1) | CN111148534A (https=) |
| WO (1) | WO2019063802A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018185135A1 (en) * | 2017-04-05 | 2018-10-11 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| BR112022001985A2 (pt) * | 2019-09-11 | 2022-05-10 | Boehringer Ingelheim Io Canada Inc | Métodos para tratamento de câncer pelo uso de inibidores do eixo pd-1 e anticorpos anti-periostina |
| CN112111575B (zh) * | 2020-09-22 | 2023-01-10 | 重庆医科大学附属第一医院 | 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| NZ597692A (en) * | 2008-12-12 | 2013-08-30 | Boehringer Ingelheim Int | Anti-IGF antibodies |
| US20130122005A1 (en) * | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| PE20170255A1 (es) * | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| SI3096792T1 (sl) * | 2014-01-24 | 2020-01-31 | Boehringer Ingelheim International Gmbh | Zdravljenje raka z uporabo antagonista receptorja insulinu podobnega rastnega faktorja (IGF) v kombinaciji z eksemestanom in everolimusom |
| EP4245376A3 (en) * | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| WO2017055291A1 (en) * | 2015-09-28 | 2017-04-06 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| CA3015913A1 (en) * | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods of treating cancer |
-
2018
- 2018-09-28 WO PCT/EP2018/076494 patent/WO2019063802A1/en not_active Ceased
- 2018-09-28 EP EP18773782.0A patent/EP3687573A1/en not_active Withdrawn
- 2018-09-28 JP JP2020517814A patent/JP2020535180A/ja active Pending
- 2018-09-28 CN CN201880063798.0A patent/CN111148534A/zh active Pending
- 2018-09-28 US US16/649,763 patent/US20200239559A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| FI3548515T3 (fi) | Radioleimattuja anti-PD-L1-vasta-aineita immuno-PET-kuvantamiseen | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| JP2013520442A5 (https=) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2020521797A5 (https=) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2019536806A5 (https=) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| JP2017031160A5 (https=) | ||
| JP2015532292A5 (https=) | ||
| FI3845245T3 (fi) | Seerumin fosfaatin efektiivinen ja tehokas säätely optimaalista luunmuodostusta varten | |
| JP2013529183A5 (https=) | ||
| JP2016502504A5 (https=) | ||
| JP2016519650A5 (https=) | ||
| JP2022511394A5 (https=) | ||
| JP2015514110A5 (https=) | ||
| RU2018123709A (ru) | Новые антитела для лечения онкологических заболеваний | |
| RU2017136709A (ru) | Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr | |
| JP2022512851A5 (https=) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2019512472A5 (https=) | ||
| JP2024533067A5 (https=) | ||
| JP2020522281A5 (https=) |